The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1539
January 29, 2018
View Complete Issue         Table of Contents 2019 
L-Glutamine (Endari) for Sickle Cell Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
L-Glutamine (Endari) for Sickle Cell Disease
January 29, 2018 (Issue: 1539)
The FDA has approved an oral powder formulation of the amino acid L-glutamine (Endari – Emmaus) to reduce the acute complications of sickle cell disease in patients ≥5 years old. Endari is only the second drug to be approved for use in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: L-Glutamine (Endari) for Sickle Cell Disease
Article code: 1539c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.